Natera Revenue 2011-2026 | NTRA

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Natera

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
820 M	625 M	391 M	302 M	258 M	211 M	217 M	190 M	159 M	55.2 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
820 M	55.2 M	323 M

Quarterly Revenue Natera

2024-Q3	2023-Q4	2023-Q3	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
440 M	-	268 M	-	-	-	194 M	-	158 M	142 M	152 M	-	98.1 M	86.5 M	94 M	83.2 M	77.9 M	74.4 M	66.8 M	67 M	65.3 M	63.1 M	62.3 M	53.8 M	56.7 M	53.6 M	46.9 M	49.3 M	53.9 M	52 M	61.9 M	52.9 M	44.9 M	45.1 M	47.4 M	49.9 M	46.3 M	35.8 M	27.3 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
440 M	27.3 M	90 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Diagnostics research industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	128 M	-	-6.23 %	$ 30.6 M	Germany
Anixa Biosciences ANIX	210 K	$ 3.03	-2.26 %	$ 98.3 K	USA
Akumin AKU	750 M	-	-17.87 %	$ 25.9 M	Canada
Aspira Women's Health AWH	8.18 M	-	-6.19 %	$ 10.5 M	USA
Biocept BIOC	25.9 M	-	-13.05 %	$ 7.29 M	USA
Brainsway Ltd. BWAY	41 M	$ 23.35	-2.91 %	$ 99.4 M	Israel
Burning Rock Biotech Limited BNR	508 M	$ 34.5	2.16 %	$ 371 M	China
Accelerate Diagnostics AXDX	2.97 M	-	-61.36 %	$ 2.46 M	USA
BioNano Genomics BNGO	30.8 M	$ 1.29	-12.26 %	$ 1.64 M	USA
Castle Biosciences CSTL	332 M	$ 39.74	1.48 %	$ 1.1 B	USA
Oxford Immunotec Global PLC OXFD	73.7 M	-	-	$ 562 M	Britain
Chembio Diagnostics CEMI	49.5 M	-	0.22 %	$ 16.8 M	USA
Co-Diagnostics CODX	6.81 M	-	-	$ 79.8 M	USA
Danaher Corporation DHR	23.9 B	$ 219.29	-0.08 %	$ 160 B	USA
Exact Sciences Corporation EXAS	2.76 B	$ 102.41	0.1 %	$ 19 B	USA
Fulgent Genetics FLGT	283 M	$ 26.19	-0.19 %	$ 792 M	USA
DermTech DMTK	15.3 M	-	-11.32 %	$ 2.94 M	USA
Global Cord Blood Corporation CO	1.24 B	-	-	$ 399 M	China
Fluidigm Corporation FLDM	138 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	6.79 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	651 M	-	0.12 %	$ 80.1 M	China
Guardant Health GH	739 M	$ 113.17	2.43 %	$ 13.9 B	USA
PRA Health Sciences, Inc. PRAH	3.18 B	-	-	$ 10.7 B	USA
DexCom DXCM	3.62 B	$ 73.31	-0.93 %	$ 28.3 B	USA
CareDx, Inc CDNA	280 M	$ 20.55	-1.23 %	$ 1.1 B	USA
DarioHealth Corp. DRIO	20.4 M	$ 10.2	-0.97 %	$ 289 M	Israel
Enzo Biochem ENZ	31.9 M	-	-8.98 %	$ 14.8 K	USA
Lantheus Holdings LNTH	1.53 B	$ 66.91	0.34 %	$ 4.63 B	USA
Heska Corporation HSKA	257 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	6.37 M	-	-20.0 %	$ 1.06 M	USA
Illumina ILMN	4.37 B	$ 144.81	-3.26 %	$ 23 B	USA
NeoGenomics NEO	661 M	$ 11.99	-3.35 %	$ 1.52 B	USA
QIAGEN N.V. QGEN	2.25 B	-	-	$ 10.6 B	Niderland
IQVIA Holdings IQV	15.4 B	$ 230.33	-2.19 %	$ 41.8 B	USA
Charles River Laboratories International CRL	4.05 B	$ 210.51	-0.59 %	$ 10.8 B	USA
Personalis PSNL	84.6 M	$ 9.33	-6.42 %	$ 553 M	USA
Medpace Holdings MEDP	2.11 B	$ 582.66	-1.76 %	$ 18 B	USA
Quest Diagnostics Incorporated DGX	9.87 B	$ 186.45	2.27 %	$ 20.7 B	USA
Biodesix BDSX	71.3 M	$ 10.11	4.66 %	$ 1.31 B	USA
Motus GI Holdings MOTS	319 K	-	-34.28 %	$ 263 K	Israel
Precipio PRPO	15.2 M	$ 24.07	-0.78 %	$ 31.2 M	USA
Laboratory Corporation of America Holdings LH	13 B	$ 271.34	0.56 %	$ 22.8 B	USA
Mettler-Toledo International MTD	3.87 B	$ 1 370.47	-1.61 %	$ 29.1 B	Schweiz
ICON Public Limited Company ICLR	5.48 B	$ 181.44	-2.39 %	$ 15 B	Irlanda
IDEXX Laboratories IDXX	3.9 B	$ 672.84	-0.57 %	$ 55.5 B	USA
Koninklijke Philips N.V. PHG	18 B	$ 28.66	-2.02 %	$ 20 B	Niderland
Agilent Technologies A	6.32 B	$ 133.33	0.07 %	$ 40.5 B	USA
Biomerica BMRA	5.31 M	$ 2.41	0.84 %	$ 5.54 M	USA